WebSep 8, 2024 · BioRay already markets an autoimmune treatment in China and is developing 10 other biologics. Quan Capital, a Shanghai healthcare venture firm, closed its second fund with $275 million in ... WebSep 18, 2024 · BEIJING – Biologics developer Hisun Bioray Bio-pharmaceutical Co. Ltd., a subsidiary of Chinese state-owned drugmaker Zhejiang Hisun Pharmaceutical Co. Ltd., received ¥3.8 billion (US$540 million) from Hong Kong investor PAG for a 58% stake in the company. "This acquisition will be the largest private equity investment in China's …
Bioraypharma/about us
WebMay 19, 2024 · As a pioneer in China's biopharmaceutical industry, BioRay started the R&D of biologics in 2003 as a core business division of Hisun Pharmaceutical, a specialty comprehensive pharmaceutical group founded in 1956. In 2024, PAG, a leading Asia-focused private equity firm, acquired the control of BioRay with an investment of … oil and lube express stanford ky
Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 …
WebDescription. Operator of a commercial-stage biopharmaceutical company with a full suite of end-to-end capabilities in China. The company specializes in discovering, developing, … WebSu preferencia se ha actualizado para esta sesión. Para cambiar permanentemente los ajustes de su cuenta, vaya a WebOct 31, 2024 · Following a bidding war, Hong Kong private equity firm PAG will pay $540 million to acquire a 58% stake in Hisun BioRay, a biologics company with a focus in autoimmune and oncology drugs. It is the largest private equity deal in China biopharma this year, according to the companies. BioRay is the biologics subsidiary of Zhejiang Hisun … oil and industrial services